Advanced Dementia: State of the Art and Priorities for the Next Decade

Susan L. Mitchell, MD, MPH; Betty S. Black, PhD; Mary Ersek, RN, PhD; Laura C. Hanson, MD, MPH; Susan C. Miller, PhD; Greg A. Sachs, MD; Joan M. Teno, MD, MS; and R. Sean Morrison, MD

Dementia is a leading cause of death in the United States. This article outlines the current understanding of advanced dementia and identifies research priorities for the next decade. Research over the past 25 years has largely focused on describing the experience of patients with advanced dementia. This work has delineated abundant opportunities for improvement, including greater recognition of advanced dementia as a terminal illness, better treatment of distressing symptoms, increased access to hospice and palliative care services, and less use of costly and aggressive treatments that may be of limited clinical benefit. Addressing those opportunities must be the overarching objective for the field in the coming decade. Priority areas include designing and testing interventions that promote high-quality, goal-directed care; health policy research to identify strategies that incentivize cost-effective and evidence-based care; implementation studies of promising interventions and policies; and further development of disease-specific outcome measures. There is great need and opportunity to improve outcomes, contain expenditures, reduce disparities, and better coordinate care for the millions of persons in the United States who have advanced dementia.


More than 5 million Americans have Alzheimer disease, and this number is expected to reach 13 million by 2050 (1) (Figure). In 2009, Alzheimer disease was the sixth-leading cause of death in the United States, a ranking that has steadily risen during the past decade (2). Aggregate health care expenditures for dementia are projected to exceed $183 billion in 2011 and reach $1.1 trillion by 2050 (3). Expenditures are highest in late-stage disease, largely because of Medicaid spending for care at nursing homes (4), where approximately 70% of these patients die (5). Altogether, the societal burden of advanced dementia is substantial and increasing.

Advanced dementia has been relatively underrecognized as a terminal illness (6–8). Initiatives aimed at improving the experience of patients dying of this disease have lagged behind those of more commonly recognized life-threatening conditions, such as cancer. Advanced dementia emerged as a topic in the scientific literature approximately 25 years ago (9). Since then, research devoted to this field has increased (10). The objectives of this article are to outline our current understanding of advanced dementia and, with that foundation, identify the most pressing research priorities for the next decade.

Current Understanding of Advanced Dementia

Clinical Course

The last year of life in persons with advanced dementia differs from that of persons with other common causes of death, in that it is characterized by a prolonged trajectory of severe disability (11). The Global Deterioration Scale (12) is a validated and reliable instrument that describes the clinical progression of dementia (Table 1). The scale ranges from stages 1 to 7, with higher scores indicating more severe dementia.

Stage 7 of the Global Deterioration Scale provides a useful description of the features of advanced dementia for clinical and research purposes: profound memory deficits (inability to recognize family members), speech limited to fewer than 5 words, total functional dependence, incontinence, and inability to ambulate. The CASCADE (Choices, Attitudes, and Strategies for Care of Advanced Dementia at the End-of-Life) study used this definition to describe the clinical course of 323 nursing home residents with advanced dementia (13). Over 18 months, 55% of the cohort died, 41% had pneumonia, 51% had a febrile episode, and 86% developed an eating problem. Other major acute illnesses (for example, hip fracture and myocardial infarction) were rare.

The CASCADE study thus confirmed that advanced dementia is characterized by a high mortality rate and the onset of infectious episodes and eating problems. Moreover, it demonstrated that most patients with advanced dementia die of this disease and its expected complications, not other acute illnesses.

Prognosis

Prognostication has important implications for clinical decision making and for accessing Medicare hospice benefits, which requires an estimated survival time of less than 6 months (13–15). The development of risk models for mortality that accurately estimate survival in advanced dementia has unfortunately proved elusive (16–21). In a prospective validation study (16), the 12-item Advanced Dementia Prognostic Tool predicted 6-month survival with only modest accuracy (area under the receiver-operating charac-
teristic curve, 0.67); however, these findings were better than those of current Medicare hospice eligibility guidelines (area under the receiver-operating characteristic curve, 0.55) (16). The difficulty of estimating 6-month survival in advanced dementia suggests that access to palliative care for these patients should be guided not by their prognosis but rather by their preference to focus care on maximizing comfort and quality of life.

Sources of Distress

Patients with advanced dementia commonly experience distressing symptoms that are amenable to treatment (6, 13, 22–29). In the CASCADE study, the proportion of nursing home residents with advanced dementia who experienced pain and dyspnea increased as death approached, in a pattern similar to that of patients with cancer who are dying (30). Assessing patients’ symptom distress is difficult because of their loss of language skills, but advanced dementia-specific instruments have been developed that quantify symptoms on the basis of the observations of caregivers. Several measures have gained greater endorsement because of their favorable psychometric properties and increasing collective experience among investigators (31–34).

Management of Common Complications

Treatment decisions in advanced dementia should be guided by patients’ care preferences as specified in advance directives or as perceived by their proxies. Goals of care must be used to guide initiation of new treatments, as well as the withdrawal of ongoing treatments. Most proxies state that comfort is the primary goal of care (13, 35), although patients with advanced dementia commonly receive treatments that are inconsistent with this goal (36–43). Possible reasons underlying this disconnect include such factors as inadequate advance care planning (40, 43, 44), the challenges of prognostication (16–21), providers giving misinformed and inconsistent counseling to proxies (13, 45), cultural influences (43, 46–48), limited access to high-quality palliative care that is tailored to the unique needs of patients with dementia (7, 39), and misaligned fiscal incentives in a fee-for-service health care system (49, 50).

Treatment choices regarding eating problems and infections are the most common decisions that proxies confront (51). A substantial body of research exists on managing feeding problems in advanced dementia (41, 44, 52–60). This topic has served as the paradigm for approaching dementia as a terminal illness with respect to examination of outcomes, decision making, and health care utilization.

Decision making for infections involves whether to administer antimicrobials or to use supportive measures only. Antimicrobial use is extensive in advanced dementia (62–66) and increases as death approaches (66). Up to 40% of patients with advanced dementia receive antimicrobials in the last 2 weeks of life (66). The extent to which antimicrobials meaningfully extend life or improve comfort in these patients, for whom infections are often a terminal event, remains unclear (38, 65, 67–69). Nursing home residents with advanced dementia are 3 times more likely than other residents to be colonized with antimicrobial-resistant bacteria (70). Altogether, the widespread use of antimicrobials in advanced dementia raises concerns not only from the perspective of individual benefits and burdens near the end of life but also from a public health standpoint with respect to the emergence of antimicrobial-resistant bacteria.

Health Care Utilization

Approximately 16% of persons in the United States who die of dementia do so in hospitals (5). Nursing home residents with advanced dementia experience an average of 1.6 hospital transfers in the last 90 days of life (42), and residents living in regions with higher transfer rates experience worse end-of-life outcomes (43). Hospitalizations can be traumatic for these frail patients (37), as they receive care from unfamiliar providers and undergo uncomfortable tests and interventions (36, 38, 42, 42).
In the CASCADE study, hospitalizations accounted for 30% of Medicare expenditures; care at skilled nursing facilities after hospitalization accounted for an additional 10% (50). Research suggests that most conditions precipitating hospitalization in advanced dementia (for example, pneumonia) can be treated with the same efficacy in the community or nursing home setting (64, 65, 71, 72). For most patients for whom comfort is the priority (13, 35), hospitalization is seldom consistent with this goal, albeit with rare exceptions (for example, a hip fracture).

Hospice care is a beneficial (26, 73–75) yet underutilized service in advanced dementia (7). Patients dying with dementia who received hospice care have better symptom management (26, 74), fewer terminal hospitalizations (76), and greater family satisfaction with care than those not receiving hospice care (28, 74). Trends indicate that hospice enrollment of patients with dementia is increasing; however, only 11% of hospice recipients in 2009 were reported to have a primary diagnosis of dementia, whereas 40% had cancer (77). Hospice professionals cite prognostication as the main hindrance to enrolling patients with dementia (78).

There are profound disparities in advanced dementia care. Nonwhite race is the most consistent risk factor associated with outcomes considered markers of poor-quality end-of-life care, including increased use of tube feeding (40), terminal hospitalizations (43), and lack of advance directives (46, 47). However, even after patient characteristics are controlled for, these outcomes vary dramatically across the United States in a strikingly consistent pattern, with a general propensity for worse quality of care in the southeast (42, 43, 48, 52, 54, 58, 79). The reasons for these disparities remain unclear, but they underscore that care of advanced dementia care is driven by a complex interplay of individual preferences, cultural influences, regional market factors, facility characteristics, local practice patterns, and health care policies.

### Strategies to Improve Care

Our understanding of successful strategies to improve care in advanced dementia is largely based on observational data. Modifiable factors most consistently shown to be associated with better palliative care outcomes for patients with advanced dementia in cohort studies include the presence of advance directives (for example, do-not-hospitalize orders) (40, 43–45, 50), better counseling of patients’ health care proxies (13, 45), residence in a special care dementia unit (45, 51), use of hospice (26, 28, 74, 76, 80), and the presence of nurse practitioners on-site in a nursing home (40, 47).

There are few randomized, controlled trials (RCTs) of interventions in advanced dementia, of which only 2 had adequate methodological rigor to warrant comment (56, 81). Both studies evaluated decision support tools. In one study, healthy elderly persons who were randomly assigned to watch a video showing a patient with advanced dementia were more likely to prefer comfort care (vs. life prolongation) than were persons who were randomly assigned to listen to a verbal description of advanced dementia (81). The second study was a cluster RCT in 24 nursing homes of a decision aid to help proxies of residents with advanced dementia make treatment decisions for feeding problems (56). Proxies in the intervention facilities (vs. the control facilities) had reduced decisional conflict, increased knowledge, and better communication with providers about feeding decisions.

### Research Priorities

To date, research has largely focused on describing the experience of patients with advanced dementia and the care they receive. This work has delineated abundant opportunities for improvement. Addressing those opportunities must be the overarching objective for advanced dementia research in the coming decade. Table 2 shows the research...
palliative care programs is a key part of the 8-month hospice eligibility guidelines are problematic equation. For example, prior work clearly shows that the broad-based palliative care programs is a key part of the Palliative care provided to these vulnerable patients (49).

Setting an intervention to avoid unwanted hospitalizations of nursing home residents with advanced dementia whose goals of care are primarily comfort. Interventions that reduce disparities in the quality of care provided to patients with advanced dementia who are of various ethnic and racial backgrounds are also needed. Clinical trials in advanced dementia, while essential, will not be straightforward to conduct; interventions are often complex, settings are not well-suited to research (for example, nursing homes), and outcomes are challenging to define and measure. Nonetheless, the success of prior RCTs that faced similar challenges demonstrates that these hurdles can be overcome (56, 71, 81, 82).

Health policy research is essential to move advanced dementia care forward. A primary goal of this research should be to identify policies that incentivize cost-effective and evidence-based care without comprising the quality of palliative care provided to these vulnerable patients (49).

Expanding access to the Medicare hospice benefit and Medicaid financing for frail elderly patients (49). The anticipated complexity of clinical interventions and policies to improve advanced dementia care necessitate the inclusion of implementation science as a key priority to ensure that they can be effectively translated into practice. The Patient Protection and Affordable Care Act presents a timely opportunity for demonstration projects that evaluate alternative financial structures to reduce unwarranted and unwanted hospitalizations for nursing home residents with advanced dementia, such as bundled payments or capitated programs, similar to the Program of All Inclusive Care for the Elderly (which integrates Medicare and Medicaid financing for frail elderly patients) (49).

Although progress has been made in outcomes measurement, many gaps remain. For example, there is no measure to quantify the stress that families of nursing home residents with advanced dementia experience. A disease-specific utility-based measure that takes into account health-related quality of life must be developed to conduct comparative effective research. Finally, greater delineation of meaningful effect sizes of existing measures is necessary to plan trials that will use these instruments as outcomes (31–34).

The research priorities set forth in this report align with those of the National Alzheimer’s Project Act, which was signed into law in January 2011. This projects calls for the expansion and coordination of research and health services delivery across federal agencies for Alzheimer disease and related dementias in order to achieve 2 top priorities: improve the health outcomes of patients with dementia and reduce the financial burden of the disease at an individual and societal level. The act further prioritizes the need to reduce disparities and improve the coordination of dementia care, and it stresses the need for initiatives aimed at prevention and early detection of dementia. However, if

<table>
<thead>
<tr>
<th>Discipline</th>
<th>Broad Research Objectives</th>
<th>Specific Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Design and conduct RCTs of interventions to promote high-quality, goal-directed care across health care settings</td>
<td>RCT of an intervention to reduce hospital transfers for nursing home residents with advanced dementia whose goal of care is comfort</td>
</tr>
<tr>
<td>Health policy/services</td>
<td>Identify policies that incentivize high-quality, cost-effective end-of-life care</td>
<td>Develop and evaluate nursing home quality indicators for end-of-life care</td>
</tr>
<tr>
<td>Implementation</td>
<td>Conduct comparative effectiveness research of treatment strategies</td>
<td>Determine the incremental cost-effectiveness ratio of not hospitalizing nursing home residents with advanced dementia for suspected pneumonia (e.g., incremental changes in quality-adjusted outcomes relative to costs)</td>
</tr>
<tr>
<td>Measurement</td>
<td>Develop new advanced dementia-specific instruments for outcomes currently lacking valid measures</td>
<td>Demonstration project of evidence-based advanced dementia care intervention into nursing home practice</td>
</tr>
<tr>
<td></td>
<td>Better establish psychometric properties of existing instruments</td>
<td>Measure of stress among family members of nursing home residents with advanced dementia</td>
</tr>
</tbody>
</table>

RCT = randomized, controlled trial.

The research priorities set forth in this report align with those of the National Alzheimer’s Project Act, which was signed into law in January 2011. This projects calls for the expansion and coordination of research and health services delivery across federal agencies for Alzheimer disease and related dementias in order to achieve 2 top priorities: improve the health outcomes of patients with dementia and reduce the financial burden of the disease at an individual and societal level. The act further prioritizes the need to reduce disparities and improve the coordination of dementia care, and it stresses the need for initiatives aimed at prevention and early detection of dementia. However, if

The anticipated complexity of clinical interventions and policies to improve advanced dementia care necessitate the inclusion of implementation science as a key priority to ensure that they can be effectively translated into practice. The Patient Protection and Affordable Care Act presents a timely opportunity for demonstration projects that evaluate alternative financial structures to reduce unwarranted and unwanted hospitalizations for nursing home residents with advanced dementia, such as bundled payments or capitated programs, similar to the Program of All Inclusive Care for the Elderly (which integrates Medicare and Medicaid financing for frail elderly patients) (49).

Although progress has been made in outcomes measurement, many gaps remain. For example, there is no measure to quantify the stress that families of nursing home residents with advanced dementia experience. A disease-specific utility-based measure that takes into account health-related quality of life must be developed to conduct comparative effective research. Finally, greater delineation of meaningful effect sizes of existing measures is necessary to plan trials that will use these instruments as outcomes (31–34).

The research priorities set forth in this report align with those of the National Alzheimer’s Project Act, which was signed into law in January 2011. This projects calls for the expansion and coordination of research and health services delivery across federal agencies for Alzheimer disease and related dementias in order to achieve 2 top priorities: improve the health outcomes of patients with dementia and reduce the financial burden of the disease at an individual and societal level. The act further prioritizes the need to reduce disparities and improve the coordination of dementia care, and it stresses the need for initiatives aimed at prevention and early detection of dementia. However, if

The anticipated complexity of clinical interventions and policies to improve advanced dementia care necessitate the inclusion of implementation science as a key priority to ensure that they can be effectively translated into practice. The Patient Protection and Affordable Care Act presents a timely opportunity for demonstration projects that evaluate alternative financial structures to reduce unwarranted and unwanted hospitalizations for nursing home residents with advanced dementia, such as bundled payments or capitated programs, similar to the Program of All Inclusive Care for the Elderly (which integrates Medicare and Medicaid financing for frail elderly patients) (49).

Although progress has been made in outcomes measurement, many gaps remain. For example, there is no measure to quantify the stress that families of nursing home residents with advanced dementia experience. A disease-specific utility-based measure that takes into account health-related quality of life must be developed to conduct comparative effective research. Finally, greater delineation of meaningful effect sizes of existing measures is necessary to plan trials that will use these instruments as outcomes (31–34).

The research priorities set forth in this report align with those of the National Alzheimer’s Project Act, which was signed into law in January 2011. This projects calls for the expansion and coordination of research and health services delivery across federal agencies for Alzheimer disease and related dementias in order to achieve 2 top priorities: improve the health outcomes of patients with dementia and reduce the financial burden of the disease at an individual and societal level. The act further prioritizes the need to reduce disparities and improve the coordination of dementia care, and it stresses the need for initiatives aimed at prevention and early detection of dementia. However, if
the top priorities of the act are to be met, significant focus must be placed on the millions of persons in the United States in the advanced stage of the disease, for whom there is great need and opportunity to improve patient outcomes, contain health care expenditures, reduce disparities, and better coordinate care.

Accomplishing these priorities will depend on several factors, including research funding. To date, roughly 63% of advanced dementia research has been supported by grants from the National Institutes of Health. However, with the National Institutes of Health budget at unprecedented lows, greater support from other federal agencies and philanthropic sources will be critical. In addition, the number of senior researchers dedicated to this field is small. Ongoing work will require close collaboration and intellectual and financial investment into the training of young investigators. Dissemination of key research findings through the education of policymakers, health care providers, and the public will be an essential step in translating this work into better advanced dementia care.

Finally, the millions of Americans with dementia and their families are perhaps the most important stakeholders in this research. Ultimately, their advocacy and enfranchisement may play the greatest role in driving advanced dementia research forward through the next decade.

From Hebrew SeniorLife, Institute for Aging Research, Boston, Massachusetts; Johns Hopkins University School of Medicine and Berman Institute of Bioethics, Baltimore, Maryland; School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Aging and Health, University of North Carolina, Chapel Hill, North Carolina; Brown University Program in Public Health and Alpert Medical School at Brown University, Providence, Rhode Island; Indiana University School of Medicine and Indiana University for Aging Research, Regenstrief Institute, Indianapolis, Indiana; and Mount Sinai School of Medicine, New York, New York.

Note: The information presented in this article is based on Research in Advanced Dementia: State of the Science and Future Directions, a conference held in Boston on 20 June 2011. This conference was funded by the National Palliative Care Research Center. Participants included the authors of this report: a group of multidisciplinary senior investigators from across the United States who are focused on advanced dementia research. Each senior investigator was assigned to review, summarize, and present the existing literature on advanced dementia in a specific area (for example, cohort definitions, clinical course, outcomes, study design, health care utilization, strategies to improve care, and funding). Each presentation was followed by group discussion with the explicit purpose of reaching consensus about key findings that were well-established by the literature. After individual topic presentations, a broader group discussion was dedicated to reaching agreement about the remaining critical knowledge gaps and the overriding top research priorities for the field.

Grant Support: By the National Palliative Care Research Center and grants K24AG033640 (Dr. Mitchell) and K24AG022345 (Dr. Morris) from the National Institute on Aging.

Potential Conflicts of Interest: Dr. Mitchell: Grant (money to institution): National Institutes of Health. Dr. Black: Employment: Johns Hopkins University; Grant (money to institution): National Institutes of Health, National Institute on Aging; Royalties: DEMeasure. Dr. Ersek: Grant (money to institution): National Institutes of Health; Support to travel to meetings for the study or other purposes: National Palliative Care Research Center, Grants/grants pending: New York Department of Health, National Institutes of Health. Dr. Miller: Support for travel to meetings for the study or other purposes: National Palliative Care Research Center; Support for travel to meetings for the study or other purposes (money to institution): National Palliative Care Research Center; Grants/grants pending: Alzheimer’s Association; Grants/grants pending (money to institution): Alzheimer’s Association. Dr. Sachs: Support for travel to meetings for the study or other purposes (money to institution): National Palliative Care Research Center; Consultancy: CVS Caremark; Grants/grants pending (money to institution): National Institutes of Health, Agency for Health-care Research and Quality, Alzheimer’s Association, National Palliative Care Research Center, Retirement Research Foundation. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2121.

Requests for Single Reprints: Susan L. Mitchell, MD, MPH, Hebrew SeniorLife, Institute for Aging Research, 1200 Centre Street, Boston, MA 02131.

Current author addresses and author contributions are available at www.annals.org.

References


Current Author Addresses: Dr. Mitchell: Hebrew SeniorLife, Institute for Aging Research, 1200 Centre Street, Boston, MA 02131.
Dr. Black: Johns Hopkins University School of Medicine and Berman Institute of Bioethics, 1809 Ashland Avenue, Baltimore, MD 21205.
Dr. Ersek: School of Nursing, University of Pennsylvania, Room 329, Fagin Hall, 418 Curie Boulevard, Philadelphia, PA 19104-4217.
Dr. Hanson: Division of Geriatric Medicine and Center for Aging and Health, University of North Carolina, 5003 Old Clinic, CB 7550, Chapel Hill, NC 27599-7550.
Drs. Miller and Teno: Brown University Program in Public Health, Department of Health Services, Policy, and Practices, Alpert Medical School at Brown University, 121 South Main Street, Providence, RI 02912.
Dr. Sachs: Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine and Indiana University for Aging Research, Regenstrief Institute, Inc., 1001 West 10th Street, OPW-M200, Indianapolis, IN 46202-2879.
Dr. Morrison: Department of Geriatrics, Box 1070, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Author Contributions: Conception and design: S.L. Mitchell, B.S. Black, L.C. Hanson, A. Sachs, R.S. Morrison.
Analysis and interpretation of the data: M. Ersek, S.C. Miller.
Drafting of the article: S.L. Mitchell, L.C. Hanson, A. Sachs, J.M. Teno, R.S. Morrison.
Critical revision of the article for important intellectual content: S.L. Mitchell, B.S. Black, M. Ersek, L.C. Hanson, S.C. Miller, A. Sachs, J.M. Teno, R.S. Morrison.
Final approval of the article: S.L. Mitchell, B.S. Black, M. Ersek, L.C. Hanson, S.C. Miller, A. Sachs, J.M. Teno, R.S. Morrison.
Obtaining of funding: S.L. Mitchell.
Administrative, technical, or logistic support: S.L. Mitchell, R.S. Morrison.
Collection and assembly of data: S.L. Mitchell, M. Ersek, S.C. Miller.